United Therapeutics Corp (UTHR-$58.62) said a late-stage trial of its experimental oral treatment for pulmonary arterial hypertension (sustained-release formulation of treprostinil) failed to meet the main goal of the study, a six-minute walking distance at Week 16, sending its shares tumbling 36 percent to a new year-low. As the 10-Q Detective warned readers back on August 27, the company was drifting into troubled waters, given the over-reliance on Remodulin for top-line growth. Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.
No comments:
Post a Comment